| Year |
Citation |
Score |
| 2023 |
Verma P, Rishi B, George NG, Kushwaha N, Dhandha H, Kaur M, Jain A, Jain A, Chaudhry S, Singh A, Siraj F, Misra A. Recent advances and future directions in etiopathogenesis and mechanisms of reactive oxygen species in cancer treatment. Pathology Oncology Research : Por. 29: 1611415. PMID 37920248 DOI: 10.3389/pore.2023.1611415 |
0.41 |
|
| 2023 |
McCarthy GA, Di Niro R, Finan JM, Jain A, Guo Y, Wyatt CR, Guimaraes AR, Waugh TA, Keith D, Morgan TK, Sears RC, Brody JR. Deletion of the mRNA stability factor (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity. Nar Cancer. 5: zcad016. PMID 37089813 DOI: 10.1093/narcan/zcad016 |
0.368 |
|
| 2023 |
McCarthy GA, Jain A, Di Niro R, Schultz CW, Jiang W, Yeo CJ, Bowers J, Finan J, Rhodes K, Casta L, Hou V, Stefanoni A, Brown SZ, Nevler A, Agostini LC, et al. A Novel 3DNA® Nanocarrier effectively delivers payloads to pancreatic tumors. Translational Oncology. 32: 101662. PMID 37004490 DOI: 10.1016/j.tranon.2023.101662 |
0.316 |
|
| 2022 |
Bhardwaj V, He J, Jain A. Glutamine stabilizes myc via alpha-ketoglutarate and regulates paclitaxel sensitivity. Medical Oncology (Northwood, London, England). 39: 227. PMID 36175776 DOI: 10.1007/s12032-022-01834-5 |
0.717 |
|
| 2022 |
Jain A, McCoy M, Coats C, Brown SZ, Addya S, Pelz C, Sears RC, Yeo CJ, Brody JR. HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms. Cancers. 14. PMID 35406624 DOI: 10.3390/cancers14071848 |
0.304 |
|
| 2021 |
Jain A, Bhardwaj V. Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. World Journal of Gastroenterology. 27: 6527-6550. PMID 34754151 DOI: 10.3748/wjg.v27.i39.6527 |
0.696 |
|
| 2021 |
Schultz CW, McCarthy GA, Nerwal T, Nevler A, DuHadaway JB, McCoy MD, Jiang W, Brown SZ, Goetz A, Jain A, Calvert VS, Vishwakarma V, Wang D, Preet R, Cassel J, et al. The FDA approved anthelmintic Pyrvinium Pamoate inhibits pancreatic cancer cells in nutrient depleted conditions by targeting the mitochondria. Molecular Cancer Therapeutics. PMID 34413127 DOI: 10.1158/1535-7163.MCT-20-0652 |
0.371 |
|
| 2020 |
Agostini LC, Jain A, Shupp A, Nevler A, McCarthy G, Bussard KM, Yeo CJ, Brody JR. Combined targeting of PARG and Wee1 causes decreased cell survival and DNA damage in an S-phase dependent manner. Molecular Cancer Research : McR. PMID 33257507 DOI: 10.1158/1541-7786.MCR-20-0708 |
0.357 |
|
| 2019 |
Dhir T, Schultz CW, Jain A, Brown SZ, Haber A, Goetz A, Xi C, Su GH, Xu L, Posey J, Jiang W, Yeo CJ, Golan T, Pishvaian MJ, Brody JR. Abemaciclib is effective against pancreatic cancer cells and synergizes with HuR and YAP1 inhibition. Molecular Cancer Research : McR. PMID 31383722 DOI: 10.1158/1541-7786.Mcr-19-0589 |
0.414 |
|
| 2019 |
Jain A, Agostini LC, McCarthy GA, Chand SN, Ramirez A, Nevler A, Cozzitorto J, Schultz CW, Lowder CY, Smith KM, Waddell ID, Raitses-Gurevich M, Stossel C, Gorman YG, Atias D, et al. Poly (ADP) ribose glycohydrolase can be effectively targeted in pancreatic cancer. Cancer Research. PMID 31273064 DOI: 10.1158/0008-5472.Can-18-3645 |
0.393 |
|
| 2019 |
Desai V, Jain A, Shaghaghi H, Summer R, Lai JCK, Bhushan A. Combination of Biochanin A and Temozolomide Impairs Tumor Growth by Modulating Cell Metabolism in Glioblastoma Multiforme. Anticancer Research. 39: 57-66. PMID 30591440 DOI: 10.21873/Anticanres.13079 |
0.711 |
|
| 2018 |
Jain A, Rani V. Assessment of herb-drug synergy to combat doxorubicin induced cardiotoxicity. Life Sciences. PMID 29752960 DOI: 10.1016/j.lfs.2018.05.021 |
0.387 |
|
| 2017 |
Jain A, Rani V. Mode of treatment governs curcumin response on doxorubicin-induced toxicity in cardiomyoblasts. Molecular and Cellular Biochemistry. PMID 28929270 DOI: 10.1007/s11010-017-3195-6 |
0.351 |
|
| 2015 |
Jain A, Lai JC, Bhushan A. Biochanin A inhibits endothelial cell functions and proangiogenic pathways: implications in glioma therapy. Anti-Cancer Drugs. 26: 323-30. PMID 25501542 DOI: 10.1097/Cad.0000000000000189 |
0.702 |
|
| 2014 |
Bhardwaj V, Tadinada SM, Jain A, Sehdev V, Daniels CK, Lai JC, Bhushan A. Biochanin A reduces pancreatic cancer survival and progression. Anti-Cancer Drugs. 25: 296-302. PMID 24201306 DOI: 10.1097/Cad.0000000000000044 |
0.669 |
|
| 2013 |
Jain A, Lai JCK, Bhushan A. Abstract 5095: Biochanin A, a natural isoflavone inhibits angiogenesis in glioma. Cancer Research. 73: 5095-5095. DOI: 10.1158/1538-7445.Am2013-5095 |
0.738 |
|
| 2012 |
Jain A, Lai JCK, Chowdhury GM, Behar K, Bhushan A. Abstract 923: Interrelations between roles of phospholipase C-gamma 1 inhibition, mTOR and glycolytic enzymes in growth and survival of glioblastoma cells Cancer Research. 72: 923-923. DOI: 10.1158/1538-7445.Am2012-923 |
0.762 |
|
| 2012 |
Frank N, Kumbulla S, Jain A, Lai J, Olson R, Cusack B, Bhushan A. Abstract 5675: Potential use of proteosome pathway inhibitor (bortezomib) in combination with anthracyclines to treat multiple myeloma and pancreatic cancer Cancer Research. 72: 5675-5675. DOI: 10.1158/1538-7445.Am2012-5675 |
0.702 |
|
| 2012 |
Dickerson L, Jain A, Crowell PL, Lai JCK, Bhushan A. Abstract 1930: Inhibition of glioblastoma cell growth with the isoprenoids perillyl alcohol, farnesol, and geraniol Cancer Research. 72: 1930-1930. DOI: 10.1158/1538-7445.Am2012-1930 |
0.71 |
|
| 2011 |
Jain A, Lai JCK, Bhushan A. Abstract 3523: Biochanin A enhances anticancer activity of temozolomide in glioblastoma multiforme Cancer Research. 71: 3523-3523. DOI: 10.1158/1538-7445.Am2011-3523 |
0.759 |
|
| 2010 |
Puli S, Jain A, Lai JC, Bhushan A. Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells. Neurochemical Research. 35: 986-93. PMID 20177775 DOI: 10.1007/S11064-010-0142-2 |
0.744 |
|
| Show low-probability matches. |